Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
OSUR 
OraSure Technologies Inc (OSUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: OSUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.83% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 176.99M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 4 | Beta 0.74 | 52 Weeks Range 2.08 - 4.22 | Updated Date 12/28/2025 |
52 Weeks Range 2.08 - 4.22 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -47.92% | Operating Margin (TTM) -58.02% |
Management Effectiveness
Return on Assets (TTM) -8.8% | Return on Equity (TTM) -15.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -29417858 | Price to Sales(TTM) 1.41 |
Enterprise Value -29417858 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 2.22 | Shares Outstanding 71733530 | Shares Floating 63667095 |
Shares Outstanding 71733530 | Shares Floating 63667095 | ||
Percent Insiders 5.95 | Percent Institutions 90.25 |
Upturn AI SWOT
OraSure Technologies Inc
Company Overview
History and Background
OraSure Technologies Inc. was founded in 1987 and is a leader in point-of-care diagnostic testing. Key milestones include the development and launch of its OraQuicku00ae rapid HIV test in 2004, which revolutionized HIV testing accessibility. The company has since expanded its portfolio to include tests for other infectious diseases, genetic disorders, and drug testing, evolving to meet critical public health needs and expanding into new markets.
Core Business Areas
- OASIS (OraSure Integrated Solutions): This segment focuses on diagnostic solutions for infectious diseases, including HIV and Hepatitis C testing. It also encompasses their molecular collection devices and diagnostic devices for a broad range of conditions.
- GenArraytion: This segment is focused on molecular diagnostics and genetic testing. It includes products like the ORA-240, a rapid genetic test for identifying individuals with a specific genetic predisposition for certain adverse drug reactions. It also includes their Next Generation Sequencing (NGS) products and services.
Leadership and Structure
OraSure Technologies Inc. is led by a management team comprising a CEO, CFO, and heads of various departments such as R&D, Sales, and Operations. The organizational structure is typically functional, with specialized teams responsible for product development, manufacturing, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- OraQuicku00ae Advanceu00ae Rapid HIV-1/2 Antibody Test: A rapid point-of-care diagnostic test for HIV. It is widely used in clinical settings, public health initiatives, and for self-testing. Competitors include Abbott Laboratories (Determineu2122 HIV-1/2 Ag/Ab Combo test) and bioMu00e9rieux (VITEKu00ae MS).
- OraQuicku00ae Viral Hepatitis Fingerstick: Rapid point-of-care tests for Hepatitis C and Hepatitis B. These tests aim to improve screening and linkage to care. Competitors include Abbott Laboratories and Roche Diagnostics.
- Interferon Gamma Release Assays (IGRAs): Tests like the QuantiFERONu00ae-TB Gold Plus (QFT-Plus) are used to detect latent tuberculosis infection. Competitors include Oxford Immunotecs (T-SPOT.TB test).
- DNA/RNA Collection Devices: Products designed for the safe and stable collection of biological samples for molecular diagnostic testing. These are crucial for downstream testing in various disease areas. Competitors include various life science reagent and consumables providers.
Market Dynamics
Industry Overview
The point-of-care diagnostics market is experiencing robust growth driven by increasing demand for rapid and accessible testing, the rising prevalence of infectious diseases, an aging global population, and technological advancements in diagnostic platforms. The molecular diagnostics segment, in particular, is expanding due to its precision and versatility.
Positioning
OraSure Technologies Inc. is well-positioned as a leader in the point-of-care testing market, particularly for infectious diseases like HIV and TB. Its strength lies in its established rapid diagnostic platforms and a growing portfolio in molecular diagnostics. The company benefits from its strong brand recognition and a history of innovation in user-friendly diagnostic solutions.
Total Addressable Market (TAM)
The global point-of-care diagnostics market is substantial and growing, with estimates projecting it to reach tens of billions of dollars in the coming years. OraSure Technologies Inc. operates within multiple segments of this TAM, including infectious disease diagnostics, molecular diagnostics, and drug testing. The company is positioned to capture a significant portion of the market share within its specialized niches, particularly in HIV and TB testing where it holds a strong presence.
Upturn SWOT Analysis
Strengths
- Established leadership in rapid HIV testing with strong brand recognition.
- Proprietary technologies for sample collection and diagnostic platforms.
- Diversified product portfolio across infectious diseases and molecular diagnostics.
- Strong relationships with public health organizations and government agencies.
- Focus on point-of-care and decentralized testing solutions.
Weaknesses
- Reliance on a few key products for a significant portion of revenue.
- Competition from larger, more diversified diagnostic companies.
- Potential for lengthy regulatory approval processes for new products.
- Susceptibility to shifts in government funding and healthcare policy.
- Need for continued investment in R&D to maintain competitive edge.
Opportunities
- Expansion into emerging markets with unmet diagnostic needs.
- Growth in molecular diagnostics and personalized medicine.
- Increased demand for infectious disease testing due to global health concerns.
- Partnerships and collaborations to expand market reach and product development.
- Development of new tests for emerging infectious diseases and chronic conditions.
Threats
- Intensifying competition and price pressures.
- Changes in regulatory landscape and reimbursement policies.
- Economic downturns impacting healthcare spending.
- Rapid technological advancements by competitors.
- Potential for product recalls or failures.
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Roche Diagnostics (Not a separate US stock symbol, part of F. Hoffmann-La Roche AG)
- Thermo Fisher Scientific (TMO)
- Becton, Dickinson and Company (BDX)
- Siemens Healthineers AG (Not a separate US stock symbol, part of Siemens AG)
Competitive Landscape
OraSure Technologies Inc. faces intense competition from larger, established players with broader product portfolios and greater R&D budgets. Its competitive advantages lie in its specialized focus on point-of-care diagnostics, particularly in infectious diseases, and its innovative sample collection technologies. However, it must continually innovate and strategically position itself to compete with the scale and resources of its larger rivals.
Growth Trajectory and Initiatives
Historical Growth: OraSure Technologies Inc. has demonstrated a history of growth, particularly driven by the success of its OraQuicku00ae product line and expansion into molecular diagnostics. Growth has been influenced by public health initiatives, demand for infectious disease screening, and strategic product launches.
Future Projections: Future growth is projected to be driven by the increasing adoption of point-of-care testing, the expansion of molecular diagnostics, and potential new product introductions. Analysts' projections often consider the company's pipeline, market trends, and its ability to penetrate new geographical regions and application areas.
Recent Initiatives: Recent initiatives may include strategic partnerships to broaden market access, investments in R&D for new diagnostic solutions, and efforts to expand manufacturing capabilities to meet growing demand. The company is also likely focusing on leveraging its existing platforms for new applications and addressing emerging public health challenges.
Summary
OraSure Technologies Inc. is a significant player in the point-of-care diagnostics market, particularly for infectious diseases. Its strengths lie in its established rapid testing platforms and growing molecular diagnostics offerings. The company is well-positioned to capitalize on the increasing global demand for accessible and rapid testing solutions. However, it faces significant competition from larger diagnostic companies and must continue to invest in innovation and strategic partnerships to maintain its growth trajectory and address potential market shifts.
Similar Stocks
Sources and Disclaimers
Data Sources:
- OraSure Technologies Inc. Investor Relations
- Company Annual Reports (10-K)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (General industry data)
Disclaimers:
This JSON output is generated based on publicly available information and general industry knowledge. It is intended for informational purposes only and should not be considered as financial advice. Actual financial performance and market share may vary. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OraSure Technologies Inc
Exchange NASDAQ | Headquaters Bethlehem, PA, United States | ||
IPO Launch date 1986-11-12 | President, CEO & Director Ms. Carrie Eglinton Manner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 501 | Website https://www.orasure.com |
Full time employees 501 | Website https://www.orasure.com | ||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.